Literature DB >> 15851005

In utero gene therapy: current challenges and perspectives.

Simon N Waddington1, M Gabriela Kramer, Ruben Hernandez-Alcoceba, Suzanne M K Buckley, Michael Themis, Charles Coutelle, Jesus Prieto.   

Abstract

Over the past few years, considerable progress in prenatal diagnosis and surgery combined with improvements in vector design vindicate a reappraisal of the feasibility of in utero gene therapy for serious monogenetic diseases. As adult gene therapy gathers pace, several apparent obstacles to its application as a treatment may be overcome by pre- or early postnatal treatment. This review will examine the concepts and practice of prenatal vector administration. We aim to highlight the advantages of early therapeutic intervention focusing on diseases that could benefit greatly from a prenatal gene therapy approach. We will pay special attention to the strategies and vectors that are most likely to be used for this application and will speculate on their expected developments for the near future.

Mesh:

Year:  2005        PMID: 15851005     DOI: 10.1016/j.ymthe.2005.01.015

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  12 in total

1.  How should risks and benefits be balanced in research involving pregnant women and fetuses?

Authors:  Carson Strong
Journal:  IRB       Date:  2011 Nov-Dec

2.  Abortion decisions as inclusion and exclusion criteria in research involving pregnant women and fetuses.

Authors:  Carson Strong
Journal:  J Med Ethics       Date:  2011-06-17       Impact factor: 2.903

3.  Minimal risk in research involving pregnant women and fetuses.

Authors:  Carson Strong
Journal:  J Law Med Ethics       Date:  2011       Impact factor: 1.718

4.  Regulatory and ethical issues for phase I in utero gene transfer studies.

Authors:  Carson Strong
Journal:  Hum Gene Ther       Date:  2011-09-23       Impact factor: 5.695

5.  Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques.

Authors:  Citra N Z Mattar; Amit C Nathwani; Simon N Waddington; Niraja Dighe; Christine Kaeppel; Ali Nowrouzi; Jenny Mcintosh; Nuryanti B Johana; Bryan Ogden; Nicholas M Fisk; Andrew M Davidoff; Anna David; Donald Peebles; Marcus B Valentine; Jens-Uwe Appelt; Christof von Kalle; Manfred Schmidt; Arijit Biswas; Mahesh Choolani; Jerry K Y Chan
Journal:  Mol Ther       Date:  2011-05-31       Impact factor: 11.454

6.  Factors determining the risk of inadvertent retroviral transduction of male germ cells after in utero gene transfer in sheep.

Authors:  Paul J Park; Evan Colletti; Ferhat Ozturk; Josh A Wood; Joe Tellez; Graça Almeida-Porada; Christopher Porada
Journal:  Hum Gene Ther       Date:  2009-03       Impact factor: 5.695

Review 7.  Delivery technologies for in utero gene therapy.

Authors:  Rohan Palanki; William H Peranteau; Michael J Mitchell
Journal:  Adv Drug Deliv Rev       Date:  2020-11-09       Impact factor: 15.470

Review 8.  A narrative review of in utero gene therapy: advances, challenges, and future considerations.

Authors:  Nicholas K Yung; Nathan L Maassel; Sarah J Ullrich; Adele S Ricciardi; David H Stitelman
Journal:  Transl Pediatr       Date:  2021-05

Review 9.  Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration.

Authors:  L D Osellame; M R Duchen
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

10.  Evidence for contribution of CD4+ CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery.

Authors:  Megha S Nivsarkar; Suzanne M K Buckley; Alan L Parker; Dany Perocheau; Tristan R McKay; Ahad A Rahim; Steven J Howe; Simon N Waddington
Journal:  J Immunol Res       Date:  2015-01-31       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.